These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8114338)

  • 1. [Aging and liver disease].
    Tanikawa K; Kamishiro R
    Nihon Ronen Igakkai Zasshi; 1993 Dec; 30(12):1026-31. PubMed ID: 8114338
    [No Abstract]   [Full Text] [Related]  

  • 2. [Contractile capacity of the myocardium in liver diseases].
    Alliluev IG
    Sov Med; 1975 Feb; (2):123-6. PubMed ID: 1145263
    [No Abstract]   [Full Text] [Related]  

  • 3. [Significane of a radiometric method of study of the cardio-portal blood circulation in patients with chronic liver diseases].
    Bondar' ZA; Novikova TF
    Klin Med (Mosk); 1967 Mar; 45(3):26-32. PubMed ID: 5604366
    [No Abstract]   [Full Text] [Related]  

  • 4. [Functional state of the cardiovascular system in chronic diffuse liver diseases].
    Bronovets IN
    Ter Arkh; 1979; 51(8):89-92. PubMed ID: 505313
    [No Abstract]   [Full Text] [Related]  

  • 5. [Liver and ageing: clinical aspects].
    Plat A; Youssef N; Brousse N; Pol S
    Gastroenterol Clin Biol; 2003 May; 27(5):540-7. PubMed ID: 12843919
    [No Abstract]   [Full Text] [Related]  

  • 6. Nuclear receptors in liver disease.
    Wagner M; Zollner G; Trauner M
    Hepatology; 2011 Mar; 53(3):1023-34. PubMed ID: 21319202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular endothelial growth factors and liver diseases.
    Shi B; Wang X; Yang Z
    Hepatogastroenterology; 2001; 48(40):1145-8. PubMed ID: 11490820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical applications of ICG Finger Monitor in patients with liver disease.
    Ishigami Y; Masuzawa M; Miyoshi E; Kato M; Tamura K; Kanda M; Awazu K; Taniguchi K; Kurita M; Hayashi N
    J Hepatol; 1993 Sep; 19(2):232-40. PubMed ID: 8301056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Osmolar and mechanic resistance of erythrocytes in chronic liver diseases].
    Konrad H; Brust B; Oldenburg G
    Z Gesamte Inn Med; 1977 Mar; 32(6):143-7. PubMed ID: 868193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Correlation between liver biopsy and clinical tests].
    Anzai T
    Rinsho Byori; 1971 Jul; 19(7):439-45. PubMed ID: 5106939
    [No Abstract]   [Full Text] [Related]  

  • 11. NX-DCP as a novel biomarker would be related to liver function in cirrhotic patients with hepatocellular carcinoma.
    Hirano H; Saito M; Seo Y; Yano Y; Azuma T
    Eur J Gastroenterol Hepatol; 2013 Jun; 25(6):748-9. PubMed ID: 23624798
    [No Abstract]   [Full Text] [Related]  

  • 12. [Fibrinolytic potential of the blood in liver damage].
    Kotschy M
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1974; 101(1):142-52. PubMed ID: 4134486
    [No Abstract]   [Full Text] [Related]  

  • 13. Regulatory T-cell directed therapies in liver diseases.
    Oo YH; Sakaguchi S
    J Hepatol; 2013 Nov; 59(5):1127-34. PubMed ID: 23727305
    [No Abstract]   [Full Text] [Related]  

  • 14. [Gastrointestinal diseases and their influence on pancreas secretion].
    Forell MM; Stahlheber H; Otte M
    Dtsch Med Wochenschr; 1969 May; 94(21):1097-101. PubMed ID: 5769145
    [No Abstract]   [Full Text] [Related]  

  • 15. Dynamics of normal and injured human liver regeneration after hepatectomy as assessed on the basis of computed tomography and liver function.
    Yamanaka N; Okamoto E; Kawamura E; Kato T; Oriyama T; Fujimoto J; Furukawa K; Tanaka T; Tomoda F; Tanaka W
    Hepatology; 1993 Jul; 18(1):79-85. PubMed ID: 8392029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endogenous bile acid tolerance test and its clinical significance--series of total bile acid levels in plasma before and after contraction of the gallbladder in patients with chronic liver diseases.
    Iwamura K
    Tokai J Exp Clin Med; 1980 Jan; 5(1):113-29. PubMed ID: 7385259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Liver and the fibrinolytic system].
    Van de Loo J
    Thromb Diath Haemorrh Suppl; 1973; 55():77-113. PubMed ID: 4612868
    [No Abstract]   [Full Text] [Related]  

  • 18. Galactose clearance in patients with hepatocellular carcinoma. Evaluation of effective hepatic blood flow.
    Meacci E; Smorlesi C; Chiarantini E; Birardi A; Buzzelli G
    Boll Soc Ital Biol Sper; 1987 Jun; 63(6):489-95. PubMed ID: 2820446
    [No Abstract]   [Full Text] [Related]  

  • 19. [Evaluation of antipyrine clearance in chronic liver diseases].
    Wang JL; Zhang F; Yuan SY
    Zhonghua Nei Ke Za Zhi; 1989 May; 28(5):295-7, 315-6. PubMed ID: 2553353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obesity and hepatocellular carcinoma.
    Caldwell SH; Crespo DM; Kang HS; Al-Osaimi AM
    Gastroenterology; 2004 Nov; 127(5 Suppl 1):S97-103. PubMed ID: 15508109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.